Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, outlines data presented at EHA 2020 evaluating matched-adjusted indirect comparisons of efficacy and safety of acalabrutinib versus ibrutinib in treatment-naïve chronic lymphocytic leukemia (CLL) patients based on data collated from the ELEVATE CLL TN study (NCT02475681) as well as the RESONATE-2 study (NCT01722487). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).